With former President Donald Trump’s election victory, the United States is preparing for a new administration and a new ...

With the American Heart Association (AHA) and American Stroke Association (ASA) updating their guidelines for preventing ...

Novo Nordisk stock inched down Wednesday after the drugmaker's weight-loss drug beat forecasts, but sales of its diabetes behemoth missed.

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its ...

Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...

Septerna's protracted initial public offering (IPO) on the Nasdaq has finally reached its conclusion, with the final amount ...

Eli Lilly ( LLY) is planning to advertise its blockbuster weight-loss drug, Zepbound, for the first time next month. Despite investor and industry recognition of the branded GLP-1 drug, "unaided ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough ...

Eli Lilly LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for ...

Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy? Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.

Lizzo is in on all the jokes with her Halloween costume this year, playfully trolling rumors that she used Ozempic to lose weight ... to feel like a sex symbol when I was growing up.

The “Dumb Blonde” podcast host shared that she’s lost 4 lbs. so far and is now “pooping normally” — but said she may be done ...